Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2004

Open Access 01-10-2004 | Research article

Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

Authors: Manuelito A Madrid, Raymundo W Lo

Published in: Breast Cancer Research | Issue 5/2004

Login to get access

Abstract

Background

Chromogenic in situ hybridization (CISH) is emerging as a practical, cost-effective, and valid alternative to fluorescent in situ hybridization in testing for gene alteration, especially in centers primarily working with immunohistochemistry (IHC).

Methods

We assessed Her-2/neu alteration using CISH on formalin-fixed paraffin-embedded primary invasive ductal carcinoma tumors in which IHC (CB11 antibody) had previously been performed, and we compared the results with IHC. The 160 selected cases were equally stratified randomly into the four IHC categories (scores of 0, 1+, 2+, and 3+). We also compared age at diagnosis and tumor histologic grade with IHC and CISH Her-2/neu.

Results

We were able to perform and evaluate CISH successfully on all cases. The agreement between 3+ IHC and CISH-amplified cases as well as between all IHC and CISH Her-2/neu negative cases was 100%, and the concordance on all positive cases was 72.50%, with an overall agreement of 86.25%. All the discordant cases had 2+ IHC scores. Although we noted Her-2/neu positivity more in premenopausal women, the age at diagnosis was not significantly associated with IHC or CISH results. Similarly, although the small group of well-differentiated tumors was apparently Her-2/neu negative in both tests, no significant association was noted between any tumor histologic grade and either IHC or CISH results.

Conclusions

CISH is easily integrated into routine testing in our laboratory. It is a necessary adjunct in determining the subset of non-amplified IHC-positive invasive tumors that will not benefit from trastuzumab therapy. Those cases with 2+ IHC results will be triaged and subjected to CISH. Her-2/neu testing should be done on all breast cancer cases regardless of age at presentation and tumor histologic grade.
Literature
1.
Popescu NC, King CR, Kraus MH: Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989, 4: 362-366.CrossRefPubMed
2.
Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of c-erbB-2 gene. A 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986, 232: 1644-1646.CrossRefPubMed
3.
Ross JS, Fletcher JA: HER-2/neu (C-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999, 112: 53-67.
4.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science. 1987, 235: 177-182.CrossRefPubMed
5.
Sjogren S, Inganas M, Lingren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998, 16: 462-469.CrossRefPubMed
6.
Borg A, Baldetorp B, Ferno M, Kilander D, Olsson H, Ryden S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 1994, 81: 137-144. 10.1016/0304-3835(94)90194-5.CrossRefPubMed
7.
Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, DePlacido S: c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996, 14: 2702-2708.CrossRefPubMed
8.
Tetu B, Brisson J, Plante V, Bernard P: p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol. 1998, 11: 823-830.PubMed
9.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17: 2639-2348.CrossRefPubMed
10.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Specificity of HercepTest in determining Her-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999, 17: 1983-1987.CrossRefPubMed
11.
Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy; apparent immunohistochemical false-positive do not get the message. J Clin Oncol. 2001, 19: 2714-2721.CrossRefPubMed
12.
Park K, Kim J, Lim S, Han S, Lee JY: Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the Her2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol. 2003, 26: 937-943. 10.1097/01.MP.0000086487.78558.7D.CrossRef
13.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer – experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-310.CrossRefPubMed
14.
Corbett IP, Henry JA, Angus B, Watchorn CJ, Wilkinson L, Hennessy C, Gullick WJ, Tuzi NL, May FE, Westley BR, et al: NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol. 1990, 161: 15-25.CrossRefPubMed
15.
Press MF, Hung G, Godolphin G, Slamon DJ: Sensitivity of Her-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994, 54: 2771-2777.PubMed
16.
Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL: Her-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001, 14: 1079-1086. 10.1038/modpathol.3880440.CrossRefPubMed
17.
Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X: Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (Her-2/neu) gene status in breast carcinoma. Mod Pathol. 2000, 13: 1238-1243. 10.1038/modpathol.3880228.CrossRefPubMed
18.
Jimenez RE, Wallis T, Tabasczka P, Visscher DW: Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000, 13: 37-45. 10.1038/modpathol.3880007.CrossRefPubMed
19.
Pauletti G, Godolphin W, Press MF: Detection and quantification of Her2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996, 13: 63-72.PubMed
20.
Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML: Her-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000, 5: 199-207. 10.1054/modi.2000.16690.CrossRefPubMed
21.
Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000, 157: 1467-1472.CrossRefPubMedPubMedCentral
22.
Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R: Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int. 2001, 51: 579-584. 10.1046/j.1440-1827.2001.01255.x.CrossRefPubMed
23.
Dandachi N, Dietze O, Hauser-Kronberger C: Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002, 82: 1007-1014.CrossRefPubMed
24.
Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z: Determination of Her2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002, 15: 657-665. 10.1038/modpathol.3880582.CrossRefPubMed
25.
Gupta D, Middleton LP, Whitaker MJ, Abrams J: Comparison of fluorescence and chromogenic in situ hybridization for detection of Her-2/neu oncogene in breast cancer. Am J Clin Pathol. 2003, 119: 381-387.CrossRefPubMed
26.
Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J: Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of Her2 status in breast cancer. Br J Cancer. 2003, 88: 1587-1591. 10.1038/sj.bjc.6600943.CrossRefPubMedPubMedCentral
27.
Park K, Kim J, Lim S, Han S, Lee JY: Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the Her2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol. 2003, 26: 937-943. 10.1097/01.MP.0000086487.78558.7D.CrossRef
28.
Vera-Roman JM, Rubio-Martinez LA: Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med. 2004, 128: 627-633.PubMed
29.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN: Her-2/neu testing in breast cancer. Pathol Patterns Rev. 2003, 120: 53-71.CrossRef
30.
Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G: Which breast carcinomas need Her2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology. 2003, 43: 354-362.CrossRefPubMed
31.
Cowell JK: Double minutes and homogeneously staining regions: gene amplification in mammalian cells. Annu Rev Genet. 1982, 16: 21-59. 10.1146/annurev.ge.16.120182.000321.CrossRefPubMed
32.
Sauer T, Wiedswang G, Boudjema G, Chirstensen H, Karesen R: Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?. APMIS. 2003, 111: 444-450. 10.1034/j.1600-0463.2003.t01-1-1110210.x.CrossRefPubMed
33.
Sidoni A, Cavaliere A, Belleza G, Scheibel M, Bucciarelli E: Breast cancer in young women: clinicopathologial features and biological specificity. Breast. 2003, 12: 247-250. 10.1016/S0960-9776(03)00095-X.CrossRefPubMed
34.
Albain KS, Allred DC, Clark GM: Breast cancer outcome and predictors of outcome: are there age differentials?. J Natl Cancer Inst Monogr. 1994, 16: 35-42.
35.
Hoff ER, Tubbs RR, Myles JL, Procop GW: Her2/neu amplification in breast cancer: stratification of tumor type and grade. Am J Clin Pathol. 2002, 117: 916-921. 10.1309/4NTU-N6K4-F8JF-EWRX.CrossRefPubMed
Metadata
Title
Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status
Authors
Manuelito A Madrid
Raymundo W Lo
Publication date
01-10-2004
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2004
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr915

Other articles of this Issue 5/2004

Breast Cancer Research 5/2004 Go to the issue

Article selection

Articles selected in July 2004

Research article

p14ARF expression in invasive breast cancers and ductal carcinoma in situ– relationships to p53 and Hdm2

Review

New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors

Commentary

A multigene RT-PCR assay used to predict recurrence in early breast cancer: two presentations with contradictory results

Book report

Lee L, Stickland V, Wilson R, Evans A: Fundamentals of Mammography, 2nd edition. London, Churchill Livingstone

Research article

Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-β and Neu pathway signaling studies: identification of a novel model for TGF-β-induced epithelial-to-mesenchymal transition
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits